CYP2C19 kit implemented in North Bristol NHS Trust
Genedrive plc has announced the upcoming implementation of its CYP2C19 ID kit in the Hyperacute and Acute Stroke Units at North Bristol NHS Trust's Southmead Hospital, a facility that treats approximately 1,500 stroke patients annually. This implementation is facilitated by an £80,000 grant from the Medlock Charitable Trust, with the hospital aiming to secure local Integrated Care Board funding for continued provision of the test post-implementation. The CYP2C19 test identifies stroke patients who may not respond to standard care, Clopidogrel, enabling more individualized treatment decisions and potentially improving long-term patient outcomes.
Select text to share a quote on X · sign in to keep highlights & notes in your GDR notes
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to report that implementation of its CYP2C19 ID kit at Bristol NHS Trust Southmead Hospital's Hyperacute and Acute Stroke Units is expected to commence shortly.
Southmead Hospital (NHS Bristol, North Somerset and South Gloucestershire Integrated Care Board (ICB)) treats approximately 1,500 stroke patients per year, and funding of £80k for the implementation has been provided to it by the Medlock Charitable Trust (Medlockcharitabletrust.org), of which David Medlock, a significant shareholder of genedrive, is Chair.
The funding will be administered through Southmead Hospital Charity, the official charity of North Bristol NHS Trust. The charity has a long-standing role in supporting enhancements to patient care across the Trust, going beyond what the NHS alone can provide.
Business case preparation by Southmead Stroke Services will progress in parallel with the aim of securing local ICB funding for the continued provision of the CYP2C19 test post the initial implementation period.
Dr Gino Miele, CEO of genedrive plc, said: "We are grateful to David and the Medlock Charitable Trust for providing the funding that enables implementation of our CYP2C19 rapid genetic test at Southmead Hospital. As a result of this support, stroke patients in the region will immediately benefit from optimised antiplatelet therapy whilst genedrive continues to engage with the ICB to secure the longer-term provision of this life saving test."
David Medlock, Chair, Medlock Charitable Trust, said: "It's a privilege to help equip our local NHS stroke medicine service with cutting edge technology which will not only help patients but also save money."
Professor Tim Whittlestone, Bristol NHS Group Chief Medical and Innovation Officer, said: "We are pleased to have the support of genedrive, which enables us to introduce point-of-care clopidogrel genotype testing within our service. This approach to stroke secondary prevention allows for more individualised treatment decisions, helping us improve long-term outcomes for our diverse Bristol patient population."
| genedrive plc | +44 (0)161 989 0245 |
| Gino Miele: CEO / Russ Shaw: CFO | https://investors.genedrive.com/s/e0025c |
| Peel Hunt LLP (Nominated Adviser and Broker) | +44 (0)20 7418 8900 |
| James Steel | |
| 5654 & Company (Media & Investor Relations) | genedrive@5654.co.uk |
| Matthew Neal | +44 (0)7917 800 011 |
| Melissa Gardiner | +44 (0)7757 697357 |
Subscribe to our news alert service: https://investors.genedrive.com/s/efea03
About genedrive plc (http://www.genedrive.com).
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.